Crosslinking proteins to RBCs (protein-RBCs) with EDC can be improved with sulfo-NHS +/- sulfo-NHS-acetate

Description:

 

Intravenous infusion of protein/peptide antigens linked to lymphocytes with ethylene carbodiimide (EDC) is a highly efficient method for inducing peripheral, antigen-specific T cell tolerance for the treatment of autoimmune disease. Likewise, red blood cells (RBC) can be used to deliver protein/peptide antigens for treatment of autoimmune disease. EDC alone to couple proteins or peptides to RBCs grossly damages RBC  membrane and reduces resistance to lytic agents.  A method using EDC, with N-hydroxysuccinimide (NHS), eliminates damage to RBC's in the current invention. RBC's can be collected with a simple blood draw versus lymphocyte collection by apheresis.

 

AURI #2016-027

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Carl Clark
Director Technology Transfer
Augusta University
caclark@augusta.edu
Inventors:
Ryan Jajosky
Rafal Pacholczyk
Gurmukh Singh
Keywords:
© 2017. All Rights Reserved. Powered by Inteum